Rough Patch For Lupin, Much Riding On Solosec, Enbrel Biosimilar
An under pressure US business dented Lupin in Q1, with a recovery seen only in the second half of FY19 as new generic products roll out. A ramp-up in on-market products like Solosec in the US and a smooth run to launch for biosimilar Enbrel in Japan and the EU, among other products, could be vital to restore momentum for the Indian firm.
You may also be interested in...
Lupin is banking on potential new product introductions and a build-up in sales of Solosec to help drive US growth momentum in the second half of fiscal 2019, but concerns over pipeline weakness persist.
Lupin’s Tarapur API site for ‘sartans’, including valsartan, has been cleared of NDMA concerns by the US FDA, and the Indian firm has also provided analytical reports to EU authorities to affirm its case. The FDA inspection, though, did end with a lone observation at the site.
Perrigo has got another Complete Response Letter on its generic version of Teva's ProAir, the company’s fourth to date, prompting a cut in its 2018 EPS guidance.